ALT - アルテアエンジニアリング (Altimmune Inc.)

ALTのニュース

   Altimmune to Report First Quarter 2022 Financial Results and Provide Business Update on May 12  2022/05/05 11:30:00 GlobeNewswire
GAITHERSBURG, Md., May 05, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2022 financial results on Thursday, May 12, 2022 and will provide a business update.
   Altimmune''s New Avatar As A Liver Disease Player  2022/04/07 09:46:06 Seeking Alpha
   Altimmune begins enrollment in phase 2 trial of pemvidutide to treat obesity  2022/04/01 13:37:05 Seeking Alpha
Altimmune (ALT) on Friday enrolled the first participant in its phase 2 MOMENTUM trial evaluating the safety and efficacy of its investigational obesity treatment…
   Altimmune, Inc. (ALT) CEO Vipin Garg on Q4 2021 Results - Earnings Call Transcript  2022/03/15 17:59:06 Seeking Alpha
   ALTIMMUNE INC (ALT) Q4 2021 Earnings Call Transcript  2022/03/15 15:30:40 The Motley Fool
ALT earnings call for the period ending December 31, 2021.
   Neo Forecast: Altcoin Continues to Underwhelm - 03 February 2022  2022/02/03 09:04:38 DailyForex
Neo initially tried to rally on Wednesday but gave back gains rather quickly as we have fallen back towards the $20 level.
   Altimmune''s Mid-Stage Pemvidutide Study Cleared By FDA For Obesity  2022/01/31 14:56:41 Benzinga
The FDA has cleared Altimmune Inc''s (NASDAQ: ALT ) Investigational New Drug (IND) application for its Phase 2 trial of pemvidutide for obesity. Pemvidutide is an investigational GLP-1/glucagon dual receptor agonist under development to treat obesity and nonalcoholic steatohepatitis (NASH). Altimmune expects to initiate the Phase 2 trial in obesity in Q1 of 2022. The Phase 2 clinical trial will enroll approximately Full story available on Benzinga.com
   Altimmune Inc Shares Near 52-Week Low - Market Mover  2022/01/11 03:56:59 Kwhen Finance
Altimmune Inc (ALT) shares closed today at 0.9% above its 52 week low of $8.10, giving the company a market cap of $329M. The stock is currently down 9.6% year-to-date, down 41.4% over the past 12 months, and up 109.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 48.5% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Industrials industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -697.0% The company's stock price performance over the past 12 months lags the peer average by 6448.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   El mercado alcista de 2022 alcanzará niveles inimaginables predice un analista que señala 6 criptomonedas que podrían dispararse más del 200%  2022/01/05 20:18:13 Cointelegraph
Los analistas creen que 2022 será el último año de un mercado alcista para Bitcoin, pero señalan que en este mercado alcista las altcoins volverán a robar la escena y subirán mucho más que BTC
   Zacks: Brokerages Anticipate Altimmune, Inc. (NASDAQ:ALT) Will Post Earnings of -$0.64 Per Share  2021/12/20 02:04:42 Transcript Daily
Equities analysts forecast that Altimmune, Inc. (NASDAQ:ALT) will report earnings per share of ($0.64) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Altimmunes earnings, with estimates ranging from ($0.89) to ($0.44). Altimmune reported earnings per share of ($0.17) during the same quarter last year, which suggests a []
   Altimmune initiates Phase 1b trial of pemvidutide in non-alcoholic fatty liver disease  2021/10/04 11:50:55 Seeking Alpha
   Altimmune Announces Initiation of 12-week Phase 1b Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease  2021/10/04 11:00:00 Intrado Digital Media
GAITHERSBURG, Md., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has enrolled the first patient in a Phase 1b clinical trial of pemvidutide (proposed INN, formerly known as ALT-801) in subjects with non-alcoholic fatty liver disease (NAFLD). Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of obesity and non-alcoholic steatohepatitis (NASH), the most severe form of NAFLD.
   SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT  2021/10/04 00:53:00 Intrado Digital Media
NEW YORK, Oct. 03, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. (Altimmune or the Company) (NASDAQ: ALT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
   Altimmune to Host Key Opinion Leader Call with Dr. Stephen Harrison on Pemvidutide Phase 1 Clinical Trial Results on September 30, 2021  2021/09/29 22:15:00 Intrado Digital Media
GAITHERSBURG, Md., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will host a Key Opinion Leader (KOL) call on its 12-week Phase 1 clinical trial of pemvidutide (proposed INN, formerly known as ALT-801) in overweight and obese subjects on Thursday, September 30, 2021 at 9:00 am EST.
   H.C. Wainwright Sees Buying Opportunity In This Biotech Stock Sell Off  2021/09/28 18:54:55 Benzinga
H.C. Wainwright said that Altimmune Inc (NASDAQ: ALT ) reported "positive" Phase 1 trial pemvidutide data, formerly known as ALT-801, in obese patients. However, shares dropped, which he sees primarily because one patient experienced elevated ALT levels that resolved after a pause in dosing. Some of the losses have since been recovered after the stock was down 20.6% as of 10:46 a.m. ET on Tuesday. Related Link: See Why Altimmune Full story available on Benzinga.com

calendar